Thymosin Alpha-1 is a synthetic peptide derived from the naturally occurring hormone thymus, which plays an important role in immune regulation. It is being studied in laboratory studies for its immunomodulatory, antiviral, and anti-inflammatory effects.
In laboratory studies, Thymosin Alpha-1 is associated with research in areas such as:
This content is for educational purposes only. It is not a recommendation for human use. The substance is intended for laboratory research only.
What is Thymosin Alpha-1?
Thymosin Alpha-1 (Tα1) is a synthetic 28-amino acid peptide derived from the naturally occurring thymosin precursor. It is being investigated in preclinical research for its immunostimulatory potential – activating T lymphocytes, enhancing NK cell efficacy, and regulating cytokine responses.
Studies have also observed an effect on modulating inflammation, supporting antiviral responses, and protecting the body in a state of immune stress.
How Thymosin Alpha-1 works
Thymosin Alpha-1 acts mainly by activating TLRs (Toll-like receptors), which are part of the innate immune system. It stimulates T-cells, increases the expression of IL-2, IFN-γ and other molecules involved in antiviral and antitumor responses. In some models, it promotes apoptosis of dysfunctional cells and increases antigen presentation.
Researched effects and interesting facts
-
Immunostimulation: increasing the number and activity of T-lymphocytes
-
Antiviral activity: support of interferon pathways (IFN‑α, IFN‑γ)
-
Anti-inflammatory effects: regulation of inflammatory cytokines
-
Support of regeneration: in immunocompromised states (e.g. after treatment)
-
NK cell stimulation: supporting natural cellular immunity
Dosage in studies
The values listed are derived solely from research studies and are not intended for real-world use outside of a laboratory environment.
-
Dose: 200–800 μg daily
-
Form: subcutaneous or intramuscular
-
Frequency: 1x daily or every other day
-
Duration: 2 - 6 weeks depending on the model
Possible side effects
- Transient irritation or tenderness at the injection site
- Mild fatigue or headache
- Rarely, nausea or temperature fluctuations
- No proven long-term toxic effects in preclinical models
Resources
- Romani, L. et al. (2004). Thymosin alpha 1: biological activities and therapeutic potential
- Garaci, E. et al. (2007). Thymosin alpha 1 in immune dysregulation and infections
- King, R. et al. (2010). Use of thymosin alpha-1 in models of immunodeficiency
This article is for informational purposes only. It does not constitute a recommendation or solicitation for use. The information provided is a summary of existing scientific literature and is for educational purposes only.
Sale
